- Home
- CYRX vs VSTM Comparison
CYRX vs VSTM Comparison
Compare CYRX & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- VSTM
- Stock Information
- Founded
- CYRX 1999
- VSTM 2010
- Country
- CYRX United States
- VSTM United States
- Employees
- CYRX N/A
- VSTM N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- VSTM Health Care
- Exchange
- CYRX Nasdaq
- VSTM Nasdaq
- Market Cap
- CYRX 365.5M
- VSTM 425.9M
- IPO Year
- CYRX N/A
- VSTM 2012
- Fundamental
- Price
- CYRX $7.55
- VSTM $4.69
- Analyst Decision
- CYRX Strong Buy
- VSTM Strong Buy
- Analyst Count
- CYRX 9
- VSTM 9
- Target Price
- CYRX $10.67
- VSTM $12.63
- AVG Volume (30 Days)
- CYRX 554.6K
- VSTM 2.6M
- Earning Date
- CYRX 08-05-2025
- VSTM 08-07-2025
- Dividend Yield
- CYRX N/A
- VSTM N/A
- EPS Growth
- CYRX N/A
- VSTM N/A
- EPS
- CYRX N/A
- VSTM N/A
- Revenue
- CYRX $232,134,000.00
- VSTM $10,000,000.00
- Revenue This Year
- CYRX N/A
- VSTM $129.06
- Revenue Next Year
- CYRX $9.63
- VSTM $306.32
- P/E Ratio
- CYRX N/A
- VSTM N/A
- Revenue Growth
- CYRX 11.75
- VSTM N/A
- 52 Week Low
- CYRX $4.58
- VSTM $2.10
- 52 Week High
- CYRX $9.78
- VSTM $9.10
- Technical
- Relative Strength Index (RSI)
- CYRX 59.40
- VSTM 39.03
- Support Level
- CYRX $7.20
- VSTM $4.60
- Resistance Level
- CYRX $7.81
- VSTM $4.90
- Average True Range (ATR)
- CYRX 0.40
- VSTM 0.32
- MACD
- CYRX 0.01
- VSTM 0.10
- Stochastic Oscillator
- CYRX 77.22
- VSTM 64.29
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.